Chronic myeloid leukaemia (CML) incidence statistics

Coronavirus (COVID-19)

We have created a central resources hub for Health Professionals which hosts all of our CRUK resources and further materials to help with managing the pandemic. We are updating the information as guidance changes. There is also a page specifically for patients on our about cancer hub.

Health Professional COVID-19 and Cancer Hub

Cases

New cases of chronic myeloid leukaemia, 2015-2017, UK.

 

Proportion of all cases

Percentage chronic myeloid leukaemia is of total cancer cases, 2015-2017, UK

 

Age

Peak rate of chronic myeloid leukaemia cases, 2015-2017, UK

 

Trend over time

Change in chronic myeloid leukaemia incidence rates since the early 1990s, UK

 

Chronic myeloid leukaemia accounted for less than 1% of all new cancer cases in the UK in 2017.[1-4]

In females in the UK, chronic myeloid leukaemia accounted for less than 1% of all new female cancer cases. In males in the UK, it accounted for less than 1% of all new male cancer cases).

46% of chronic myeloid leukaemia cases in the UK are in females, and 54% are in males.

Chronic myeloid leukaemia incidence rates (European age-standardised (AS) rates Open a glossary item) for persons are similar to the UK average in all the UK constituent countries.

Chronic Myeloid Leukaemia (C92.1), Number of New Cases, Crude and European Age-Standardised (AS) Incidence Rates per 100,000 Population, UK, 2017

  England Scotland Wales Northern Ireland UK
Female Cases 333 30 17 4 384
Crude Rate 1.2 1.1 1.1 0.4 1.1
AS Rate 1.2 1.1 1.0 0.5 1.2
AS Rate - 95% LCL 1.1 0.7 0.6 0.0 1.0
AS Rate - 95% UCL 1.3 1.4 1.5 0.9 1.3
Male Cases 387 30 17 11 445
Crude Rate 1.4 1.1 1.1 1.2 1.4
AS Rate 1.6 1.2 1.1 1.4 1.5
AS Rate - 95% LCL 1.4 0.8 0.6 0.6 1.4
AS Rate - 95% UCL 1.7 1.7 1.7 2.3 1.6
Persons Cases 720 60 34 15 829
Crude Rate 1.3 1.1 1.1 0.8 1.3
AS Rate 1.4 1.1 1.1 0.9 1.3
AS Rate - 95% LCL 1.3 0.8 0.7 0.5 1.2
AS Rate - 95% UCL 1.5 1.4 1.5 1.4 1.4

95% LCL and 95% UCL are the 95% lower and upper confidence limits Open a glossary item around the AS Rate Open a glossary item

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, November 2019. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2019. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, December 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2017, ICD-10 C92.1.

Last reviewed:

Chronic myeloid leukaemia incidence is related to age, with the highest incidence rates being in older people. In the UK in 2015-2017, on average each year almost a quarter of new cases (23%) were in people aged 75 and over.[1-4]

Age-specific incidence rates rise gradually from birth and more steeply from around age 65-69. The highest rates are in the 85 to 89 age group for females and males.

Incidence rates are similar between females and males in most age groups.

Chronic myeloid leukaemia (C92.1), Average Number of New Cases per Year and Age-Specific Incidence Rates per 100,000 Population, UK, 2015-2017

For chronic myeloid leukaemia, like most cancer types, incidence increases with age. This largely reflects cell DNA damage accumulating over time. Damage can result from biological processes or from exposure to risk factors. A drop or plateau in incidence in the oldest age groups often indicates reduced diagnostic activity perhaps due to general ill health.

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, November 2019. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2019. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, December 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 2015-2017, C92.1.

Last reviewed:

Chronic myeloid leukaemia European age-standardised (AS) Open a glossary item incidence rates for females and males combined decreased by 30% in the UK between 1993-1995 and 2015-2017.[1-4] The decrease was larger in males than in females.

For females, chronic myeloid leukaemia AS incidence rates in the UK decreased by 24% between 1993-1995 and 2015-2017. For males, chronic myeloid leukaemia AS incidence rates in the UK decreased by 40% between 1993-1995 and 2015-2017.

Over the last decade in the UK (between 2005-2007 and 2015-2017), chronic myeloid leukaemia AS incidence rates for females and males combined remained stable. In females AS incidence rates remained stable, and in males rates remained stable.

Chronic Myeloid Leukaemia (ICD-10 C92.1), European Age-Standardised Incidence Rates, UK, 1993-2017

Chronic myeloid leukaemia incidence rates have remained stable overall in some broad age groups in females and males combined in the UK since the early 1990s, but have increased or decreased in others.[1-4] Rates in 0-24s have remained stable, in 25-49s have increased by 33%, in 50-59s have remained stable, in 60-69s have remained stable, in 70-79s have decreased by 48%, and in 80+s have decreased by 66%.

Chronic Myeloid Leukaemia (ICD-10 C92.1), European Age-Standardised Incidence Rates, By Age, UK, 1993-2017

For chronic myeloid leukaemia there are few established risk factors, therefore increasing incidence in the 1980s and 1990s may largely reflect improvements in diagnosis and data recording, plus changes in the definition of CML.

References

  1. Data were provided by the National Cancer Registration and Analysis Service (part of Public Health England), on request through the Office for Data Release, November 2019. Similar data can be found here: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/previousReleases
  2. Data were provided by ISD Scotland on request, April 2019. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications.
  3. Data were provided by the Welsh Cancer Intelligence and Surveillance Unit, Health Intelligence Division, Public Health Wales on request, December 2019. Similar data can be found here: http://www.wcisu.wales.nhs.uk.
  4. Data were provided by the Northern Ireland Cancer Registry on request, May 2019. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.

About this data

Data is for UK, 1993-2017, ICD-10 C92.1.

Last reviewed:

There is no evidence for an association between chronic myeloid leukaemia (CML) incidence and deprivation for either males or females in England.[1] England-wide data for 2006-2010 show European age-standardised Open a glossary item  incidence rates are similar for both males and females living in the most deprived areas compared with the least deprived.[1]

Chronic Myeloid Leukaemia (C92.1), European Age-Standardised Incidence Rates by Deprivation Quintile, England, 2006-2010

The estimated deprivation gradient in CML incidence between people living in the most and least deprived areas in England has not changed in the period 1996-2010.[1]

Reference

  1. Cancer Research UK and National Cancer Intelligence Network. Cancer by deprivation in England: Incidence, 1996-2010, Mortality, 1997-2011. London: NCIN; 2014.

About this data

Data is for: England, 2006-2010, ICD-10 C92.1

Deprivation gradient statistics were calculated using incidence data for 2006-2010. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.

Last reviewed:

An estimated 6,000 people who had been diagnosed with chronic myeloid leukaemia (CML) between 1991 and 2010 were alive in the UK at the end of 2010.[1]

References

  1. Macmillan Cancer Support and National Cancer Registration and Analysis Service. Cancer Prevalence UK Data Tables. London: NCRAS; 2015.

About this data

Data is for: Great Britain (1991-2010) and Northern Ireland (1993-2010), ICD-10 C92.1

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.

@CRUKHCPs

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.